The phase II trial EV-201 with Enfortumab vedotin enrolled patients with locally advanced urothelial carcinoma previously treated with PD-1/PD-L1 inhibitor and/or platinum-containing chemotherapy. Here, CD274 is linked to urothelial carcinoma.